R&D channel feed – Endpoints News

R&D channel feed

I/O enthusiast Servier signs up for an $807M, second wave PD-1 development deal with Sorrento

9 years ago

Sucampo shutters development effort after lead drug flops in back-to-back studies

9 years ago

FDA offers Novartis a thumbs-up on Enbrel biosimilar as Amgen plays offense/defense simultaneously

9 years ago

Celyad bounces back from heart study flop to ink a $312M I/O deal with Ono

9 years ago

Juno scrambles to avoid being crushed by a hold, but experts question its best case scenario

9 years ago

GlaxoSmithKline cautiously follows Sanofi, ramps up a new project for Zika with the NIH

9 years ago

Amgen tees up a swift approval for a franchise destroyer aimed at AbbVie’s $14B drug Humira

9 years ago

Juno’s lead CAR-T slammed with a clinical hold in the last lap ahead of FDA filing

9 years ago

New U.K. translational research effort will test if ketamine can halt alcoholism

9 years ago

KaloBios binds up Martin Shkreli and cages his stock in a long goodbye

9 years ago

AbbVie preps franchise decision after Ablynx’s IL-6 drug goes head-to-head against Actemra

9 years ago

Stalled at the FDA, Amicus adds a preclinical rare disease drug in back-ended $90M deal

9 years ago

The wild card: Just how much is Medivation’s talazoparib worth?

9 years ago

It’s not easy being 5th: Pfizer and Merck KGaA blueprint a new attack on ovarian cancer

9 years ago

Trendy Moderna's single-asset CF pact with Vertex marks a new phase of dealmaking

9 years ago

Biotech IPOs may still be a bright spot, but the light has dimmed

9 years ago

Using money honey instead of threats, Sanofi wins a seat at the bargaining table for Medivation buyout

9 years ago

XBiotech shares tank after PhIII data get a roasting

9 years ago

Pfizer sets up Bind auction with $20M stalking horse bid

9 years ago

Death watch: Epirus Bio joins the growing list of biotech failures headed for the scrap heap

9 years ago

Takeda hands TiGenix a rare, $434M marketing deal for PhIII stem cell therapy

9 years ago

Bristol-Myers bags a new tumor microenvironment drug for next-gen cancer combos

9 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2016

9 years ago

AstraZeneca shuffles the deck, deals out a new hand for two troubled drugs

9 years ago

First page Previous page 327 328 329330331 332 Next page Last page